We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Read MoreHide Full Article
Key Takeaways
Opdivo and Qvantig sales rose in Q3, with Bristol Myers expecting strong global growth in 2025.
Gains are driven by demand in key markets and new approvals, including strong U.S. and ex-U.S. momentum.
Bristol Myers faces pressure from rivals Keytruda and Tecentriq as it offsets declines in legacy treatments.
Bristol Myers (BMY - Free Report) has a robust oncology portfolio, including the blockbuster immune-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others.
Opdivo is a key drug in BMY’s growth portfolio that is approved for several oncology indications. The drug, approved for numerous oncology indications, is one of the top revenue generators for BMY.
Consistent label expansion of the drug has enabled it to maintain momentum. Opdivo sales were approximately $2.5 billion in the third quarter, up 7%, driven primarily by continued demand. U.S. sales are being driven by a strong launch in MSI-high colorectal cancer and continued growth in first-line non-small cell lung cancer, while international sales are supported by label expansions of the drug.
The approval of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use has bolstered Opdivo’s franchise. The initial uptake has been strong. Sales totaled $67 million in the third quarter, fueled by continued use across all indicated tumor types as well as the permanent J-Code received in the quarter.
The company now expects global Opdivo sales, together with Qvantig, to increase in the high single digit to low double-digit range in 2025 (previous guidance: mid to high single-digit range in 2025), driven by strong performance year to date.
We note that BMY is currently banking on the label expansion of approved drugs and approval of new drugs to stabilize its revenue base, as its legacy drugs (Revlimid, Pomalyst, Sprycel and Abraxane) face generic competition.
Competition for BMY’s Oncology Drugs
While the label expansion of Opdivo is positive, the immuno-oncology space is dominated by pharma giant Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab), along with Roche’s (RHHBY - Free Report) Tecentriq.
Keytruda is approved for several types of cancer and alone accounts for more than 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Roche’s immuno-oncology Tecentriq is also approved for various oncology indications — early-stage (adjuvant) NSCLC, small cell lung cancer, hepatocellular carcinoma and breast cancer, among others. In addition to intravenous infusion, Roche has also obtained approval for Tecentriq as a subcutaneous injection.
BMY’s Price Performance, Valuation and Estimates
Shares of Bristol Myers have lost 12.9% year to date against the industry’s growth of 19.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 8.17x forward earnings, lower than its mean of 8.40x and the large-cap pharma industry’s 17.47X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has moved north in the past 60 days, while that for 2026 EPS has moved south.
Image: Shutterstock
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Key Takeaways
Bristol Myers (BMY - Free Report) has a robust oncology portfolio, including the blockbuster immune-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others.
Opdivo is a key drug in BMY’s growth portfolio that is approved for several oncology indications. The drug, approved for numerous oncology indications, is one of the top revenue generators for BMY.
Consistent label expansion of the drug has enabled it to maintain momentum. Opdivo sales were approximately $2.5 billion in the third quarter, up 7%, driven primarily by continued demand. U.S. sales are being driven by a strong launch in MSI-high colorectal cancer and continued growth in first-line non-small cell lung cancer, while international sales are supported by label expansions of the drug.
The approval of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use has bolstered Opdivo’s franchise. The initial uptake has been strong. Sales totaled $67 million in the third quarter, fueled by continued use across all indicated tumor types as well as the permanent J-Code received in the quarter.
The company now expects global Opdivo sales, together with Qvantig, to increase in the high single digit to low double-digit range in 2025 (previous guidance: mid to high single-digit range in 2025), driven by strong performance year to date.
We note that BMY is currently banking on the label expansion of approved drugs and approval of new drugs to stabilize its revenue base, as its legacy drugs (Revlimid, Pomalyst, Sprycel and Abraxane) face generic competition.
Competition for BMY’s Oncology Drugs
While the label expansion of Opdivo is positive, the immuno-oncology space is dominated by pharma giant Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab), along with Roche’s (RHHBY - Free Report) Tecentriq.
Keytruda is approved for several types of cancer and alone accounts for more than 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Roche’s immuno-oncology Tecentriq is also approved for various oncology indications — early-stage (adjuvant) NSCLC, small cell lung cancer, hepatocellular carcinoma and breast cancer, among others. In addition to intravenous infusion, Roche has also obtained approval for Tecentriq as a subcutaneous injection.
BMY’s Price Performance, Valuation and Estimates
Shares of Bristol Myers have lost 12.9% year to date against the industry’s growth of 19.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 8.17x forward earnings, lower than its mean of 8.40x and the large-cap pharma industry’s 17.47X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has moved north in the past 60 days, while that for 2026 EPS has moved south.
Image Source: Zacks Investment Research
BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.